KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

No major effect of age (< 40 vs. ≥ 40 years) on response to secukinumab in patients with axSpA: a post hoc analysis of six phase 3 trials.

Sofia Ramiro, Corine Gaillez, Uta Kiltz, Lianne S Gensler, Chaitali Pisal, Jurgen Braun, Alexis Ogdie

Arthritis Res Ther 28(1) 112

PMID41965705
PMCIDPMC13188467
DOI10.1186/s13075-026-03804-y
发表日期2026-04-11
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1:图注未提示 KM 曲线;Fig. 2:图注未提示 KM 曲线;Fig. 3:非 KM 图;Fig. 4:图注未提示 KM 曲线。
摘要

摘要

BACKGROUND: Secukinumab is an interleukin (IL)-17 inhibitor approved to treat patients with axial spondyloarthritis (axSpA), including radiographic (r)-axSpA and non-radiographic (nr)-axSpA. Treatment recommendations highlight the importance of individualized treatment of patients with axSpA according to symptoms, extra-musculoskeletal manifestations, and comorbidities. The objective of this post hoc analysis was to compare clinical responses to secukinumab treatment through Week 16 between younger and older patients with r-axSpA and nr-axSpA from six placebo-controlled phase 3 clinical studies. METHODS: This post hoc analysis evaluated data pooled from 1427 patients with axSpA from the MEASURE 1-5 trials (NCT01358175, NCT01649375, NCT02008916, NCT02159053, and NCT02896127) and the PREVENT trial (NCT02696031). All patients were randomized to secukinumab 150 mg, 300 mg, or placebo through Week 16. Patient subgroups were defined based on median age at baseline (18 to < 40 years vs. ≥ 40 years). Treatment effect (secukinumab 150/300 mg vs. placebo) within each age subgroup and the difference in treatment effect between younger vs. older age subgroups were assessed. RESULTS: Secukinumab treatment demonstrated clinical efficacy and improvements in patient-reported outcomes vs. placebo at Week 16 in patients with r-axSpA or nr-axSpA irrespective of age. No difference in treatment effect of ASAS20, ASAS40, or ASDAS response was observed between younger vs. older patients with r-axSpA or nr-axSpA (all P>.05). Among patients with r-axSpA, younger patients experienced a larger treatment effect of secukinumab on SF-36 than older patients (difference in least-squares mean [LSM]: 2.2; P < .05). Among patients with nr-axSpA, younger patients experienced a larger treatment effect of secukinumab on the Berlin SIJ total edema score (difference in LSM: - 1.2; P < .05) and Total ASspi-MRI-a score (LSM, - 0.4; P<.05). CONCLUSION: Clinical efficacy of secukinumab vs. placebo at Week 16 was generally similar between older and younger patients with either r-axSpA or nr-axSpA.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Efficacy of secukinumab vs. placebo for binary outcomes at Week 16 across age groups. Achievement of efficacy outcomes at Week 16 with secukinumab vs. placebo across age groups for patients with ( A ) r-axSpA (MEASURE 1–5) or ( B ) nr-axSpA (PREVENT). ASAS, Assessment of SpondyloArthritis international Society; ASDAS, Axial Spondyloarthritis Disease Activity Score; CII, clinically important improvement; ID, inactive disease; nr-axSpA, non-radiographic axial spondyloarthritis; r-axSpA, radiographic axial spondyloarthritis. Responses missing for any reason are imputed as non-responders
非 KM Figure
Fig. 2Difference in treatment effects of secukinumab for binary outcomes between age groups. Effect of age on the achievement of clinical response among patients at Week 16 as determined by the difference in treatment effects (secukinumab vs. placebo) between age groups (younger vs. older patients) for patients with ( A ) r-axSpA or ( B ) nr-axSpA. ASAS, Assessment of SpondyloArthritis international Society; ASDAS, Axial Spondyloarthritis Disease Activity Score; CII, clinically important improvement; ID, inactive disease; nr-axSpA, non-radiographic axial spondyloarthritis; r-axSpA, radiographic axial spondyloarthritis; TNFi, tumor necrosis factor inhibitor. Responses missing for any reason are imputed as non-responders. The logistic regression adjusted for sex, obesity, previous TNFi experience, cardiovascular disease, uveitis, and psoriasis as covariates. a The older patient group was used as the reference category for the treatment effect comparison by age group
非 KM Figure
Fig. 3Efficacy of secukinumab vs. placebo for continuous outcomes at Week 16 across age groups. Change from baseline in continuous outcomes at Week 16 with secukinumab vs. placebo across age groups (younger vs. older) among patients with ( A ) r-axSpA or ( B ) nr-axSpA. ANCOVA, analysis of covariance; BASFI, Bath Ankylosing Spondylitis Functional Index; LSM, least-squares mean; nr-axSpA, non-radiographic axial spondyloarthritis; r-axSpA, radiographic axial spondyloarthritis; SF-36 PCS, 36-Item Short Form Health Survey physical component summary; SIJ, sacroiliac joint. a Mixed-model for repeated measures. b ANCOVA. c Among patients with r-axSpA, Berlin SIJ total edema, Berlin total spine, and total ASspi-MRI-a scores were only available from MEASURE-1
非 KM Figure
Fig. 4Difference in treatment effects of secukinumab between age groups for continuous outcomes. Effect of age on the change from baseline in continuous outcomes among patients at Week 16 as determined by the difference in treatment effects (secukinumab vs. placebo) between age groups (younger vs. older) for patients with ( A ) r-axSpA or ( B ) nr-axSpA. BASFI, Bath Ankylosing Spondylitis Functional Index; LSM, least-squares mean; nr-axSpA, non-radiographic axial spondyloarthritis; r-axSpA, radiographic axial spondyloarthritis; SF-36 PCS, 36-Item Short Form Health Survey physical component summary; SIJ, sacroiliac joint. The logistic regression adjusted for sex, obesity, previous TNFi experience, cardiovascular disease, uveitis, and psoriasis as covariates. a The older patient group was used as the reference category for the treatment effect comparison by age group. For BASFI, Berlin SIJ total edema, Berlin total spine, and total ASspi-MRI-a scores, a negative value indicates a greater treatment effect among younger patients; for SF-36 PCS, a positive value indicates a greater treatment effect among younger patients
非 KM Figure